Supervised lifestyle intervention from a medical professional may help maximize fat loss and minimize muscle tissue loss in people taking the potent weight loss drugs.

Pooled annual prevalence of GLP-1 RA use was 0.1 percent from 2018 to 2021 and increased to 0.4 percent by 2022.

Combination therapy with GLP-1 RAs and thiazolidinediones is associated with a reduced risk for mortality in patients with T2D, a study finds.

A real-world study finds cardiovascular and survival benefits from dual therapy in patients with type 2 diabetes.

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

The U.S. Phase 2 trial aims to evaluate efficacy and safety of CX11 in doses up to 200 mg and different titration schemesThe trial is expected to ...

Shelf-stable vaccine patch maker Vaxess Technologies announced today that it received an additional $9 million in funding.

Pfizer has terminated the development of its oral obesity candidate danuglipron after a patient on a clinical trial with the ...

Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid ...

Researchers from the University of Bern analyzed over 300,000 FDA reports and found semaglutide use was linked to a higher ...

Cade Shadbolt, from the University of Melbourne in Australia, and colleagues examined data from the Medical Expenditure Panel Survey Household Component from 2018 to 2022 to examine GLP-1 RA use ...